The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome. — CFSMEATLAS
The effects of galantamine hydrobromide treatment on dehydroepiandrosterone sulfate and cortisol levels in patients with chronic fatigue syndrome.
Turan, Tayfun, Izgi, Hasan Basri, Ozsoy, Saliha et al. · Psychiatry investigation · 2009 · DOI
Quick Summary
This study tested whether a medication called galantamine, which increases a brain chemical called acetylcholine, could help ME/CFS patients by improving hormone imbalances. Researchers measured two stress hormones (cortisol and DHEAS) in 29 ME/CFS patients before and after 4 weeks of treatment, comparing them to healthy controls. They found that in patients who improved with the medication, the abnormal hormone levels shifted back toward normal, suggesting the cholinergic system may play a role in ME/CFS.
Why It Matters
This study provides mechanistic evidence that brain chemistry imbalances in ME/CFS may be addressable through cholinergic modulation, offering a biological rationale for symptom-targeted treatment approaches. Understanding hormonal dysfunction in ME/CFS could lead to new diagnostic biomarkers and therapeutic options for cognitive dysfunction and fatigue.
Observed Findings
ME/CFS patients had significantly lower baseline cortisol levels than healthy controls (p=0.049)
ME/CFS patients had higher baseline DHEAS levels and DHEAS/cortisol ratios than controls
In treatment-responsive patients, DHEAS levels decreased and normalized after 4 weeks of galantamine (p=0.029)
In treatment-responsive patients, DHEAS/cortisol molar ratios normalized after galantamine treatment (p=0.025)
7 of 22 patients who completed the study were classified as non-responders based on Newcastle Research Group ME/CFS Score Card
Inferred Conclusions
Cholinergic deficit may contribute to hypothalamic-pituitary-adrenal axis hypoactivity in ME/CFS
Galantamine-induced normalization of hormone ratios in responders supports the cholinergic hypothesis as mechanistically relevant to ME/CFS pathophysiology
Abnormal stress hormone patterns in ME/CFS may be partially reversible through cholinergic modulation
Remaining Questions
Why do only some patients respond to galantamine treatment, and what distinguishes responders from non-responders?
Do normalized hormone levels correspond to clinical symptom improvement, and are these changes sustained beyond 4 weeks?
What This Study Does Not Prove
This study does not prove that galantamine is an effective treatment for ME/CFS as a whole—only that it normalized certain hormone ratios in responders over 4 weeks. It cannot establish causation between cholinergic deficit and ME/CFS, only association. The lack of placebo control and small sample size prevent conclusions about treatment efficacy or broader applicability.